The functional characterization of normal and neoplastic human enterochromaffin cells

Irvin M Modlin1, Mark Kidd, Roswitha Pfragner

  • 1Department of Surgery, TMP202, Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut 06520, USA. imodlin@optonline.net

Abstract

Insights

Researchers developed a new method to isolate pure human enterochromaffin (EC) cells, enabling the study of small intestinal neuroendocrine regulation and carcinoid tumors. This advance identifies potential targets for controlling carcinoid tumor growth and secretion.

Area of Science:

  • Gastroenterology
  • Neuroendocrinology
  • Oncology

Background:

  • Small intestinal (SI) neuroendocrine regulation is poorly understood due to the unavailability of pure neuroendocrine cells.
  • The biological basis of SI carcinoid tumors remains unknown because neoplastic human enterochromaffin (EC) cells are unavailable.

Purpose of the Study:

  • To define the secretory regulation of naive and neoplastic SI neuroendocrine cells.
  • To determine the transcriptome of naive and neoplastic SI neuroendocrine cells.

Main Methods:

  • Isolation and purification of EC cells from human ilea using enzymatic digestion, density gradient centrifugation, and fluorescence-activated cell sorting (FACS).
  • Characterization of a malignant EC cell carcinoid cell line (KRJ-I).
  • Measurement of serotonin (5-HT) secretion and cAMP levels in response to various stimuli, and transcriptome profiling of normal and neoplastic EC cells.

Main Results:

  • FACS yielded highly pure EC cells (>99%) with significantly enriched serotonin content.
  • Differential regulation of 5-HT secretion by various agonists (e.g., isoproterenol, acetylcholine, GABA(A)) was observed between naive and neoplastic EC cells.
  • Transcriptome analysis revealed shared neuroendocrine markers and identified unique genes associated with carcinoid malignancy (MTA1, MAGE-D2).

Conclusions:

  • Novel methodology enables purification of live human EC cells for functional and transcriptomic assessment.
  • This approach facilitates the identification of new therapeutic targets for controlling SI carcinoid secretion and proliferation.